Other companies may be struggling to meet expectations for financial performance, but not Varian Medical Systems. On April 8, the company said its earnings for 2Q 2003 would rise 35% to 40% over the year-ago quarter. Previously, the company estimated 26%
Other companies may be struggling to meet expectations for financial performance, but not Varian Medical Systems. On April 8, the company said its earnings for 2Q 2003 would rise 35% to 40% over the year-ago quarter. Previously, the company estimated 26% growth for the quarter. The better-than-expected earnings reflect a recovery much stronger than was anticipated in the x-ray products business, according to Varian. The company is also reporting continued strength in its oncology business. The strong quarter puts annual company earnings per diluted share for fiscal 2003 on track to grow by 29% to 31% over fiscal 2002 totals.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.